Over the past 60 years, chemotherapeutic agents that target thymidylate biosynthesis and
the enzyme thymidylate synthase (TS) have remained among the most-successful drugs …

Non-small cell lung cancer (NSCLC), which represents 80–85% of lung cancer cases, is one
of the leading causes of human death worldwide. The majority of patients undergo an …

Efficacy of chemotherapy in the treatment of distinct malignancies is often hampered by drug
resistance arising in the tumor. Understanding the molecular basis of drug resistance and …

Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related
death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and …

Base excision repair (BER) has evolved to preserve the integrity of DNA following cellular
oxidative stress and in response to exogenous insults. The pathway is a coordinated …

Thymidylate synthase is the rate-limiting enzyme required for DNA synthesis and
overexpression of this enzyme causes resistance to cancer cells. Long treatments with 5-FU …

DNA nanostructure-based responsive drug delivery has become an increasingly potent
method in cancer therapy. However, a variety of important cancer biomarkers have not been …

Base excision repair (BER) repairs mutagenic or genotoxic DNA base lesions, thought to be
important for both the etiology and treatment of cancer. Cancer phenotypic stress induces …

Our current understanding of the mechanisms of action of antitumor agents and the precise
mechanisms underlying drug resistance is that these two processes are directly linked …

Currently, lung cancer has remained the most common cause of cancer death while non-
small cell lung cancer (NSCLC) accounts for the most of all lung cancer cases. Regardless …